https://www.abcellera.com https://www.abcellera.com/pipeline https://www.abcellera.com/about https://www.abcellera.com/platform https://www.abcellera.com/careers https://www.abcellera.com/partnering https://www.abcellera.com/news https://www.abcellera.com/contact-us https://www.abcellera.com/publications https://www.abcellera.com/press-kit https://www.abcellera.com/privacy-policy https://www.abcellera.com/sitemap https://www.abcellera.com/current-openings https://www.abcellera.com/policies-commitments https://www.abcellera.com/news/16th-annual-pegs-boston https://www.abcellera.com/news/aacr-annual-meeting-2022 https://www.abcellera.com/news/aacr-annual-meeting-2023 https://www.abcellera.com/news/aacr-annual-meeting-2024 https://www.abcellera.com/news/aacr-annual-meeting-2025 https://www.abcellera.com/news/abcellera-acquires-lineage-biosciences https://www.abcellera.com/news/abcellera-acquires-orthomab-bispecific-platform-to-propel-the-development-of-antibody-therapies-for-pharma-and-biotech-partners https://www.abcellera.com/news/abcellera-acquires-tetragenetics-enhancing-capabilities-to-generate-antibodies-against-high-value-targets https://www.abcellera.com/news/abcellera-and-abbvie-partner-to-advance-new-antibody-therapies https://www.abcellera.com/news/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients https://www.abcellera.com/news/abcellera-and-bruker-reach-global-settlement-of-patent-litigation https://www.abcellera.com/news/abcellera-and-denali-therapeutics-sign-expanded-multi-year-multi-target-deal-to-discover-therapeutic-antibodies-for-neurological-diseases https://www.abcellera.com/news/abcellera-and-empirico-announce-strategic-multi-target-antibody-discovery-collaboration https://www.abcellera.com/news/abcellera-and-empirico-expand-strategic-multi-target-antibody-discovery-collaboration https://www.abcellera.com/news/abcellera-and-everest-medicines-announce-multi-target-collaboration-to-advance-new-antibody-therapies https://www.abcellera.com/news/abcellera-and-gilead-sciences-announce-new-multi-year-multi-target-antibody-discovery-collaboration https://www.abcellera.com/news/abcellera-and-harbour-antibodies-announce-technology-co-offering-agreement-for-next-generation-fully-human-antibody-discovery https://www.abcellera.com/news/abcellera-and-igm-biosciences-announce-multi-year-antibody-discovery-collaboration https://www.abcellera.com/news/abcellera-and-invetx-expand-multi-year-antibody-discovery-collaboration-in-animal-health https://www.abcellera.com/news/abcellera-and-kodiak-sciences-enter-second-antibody-discovery-collaboration-for-ophthalmology-targets https://www.abcellera.com/news/abcellera-and-lilly-expand-collaboration-to-develop-antibody-medicines https://www.abcellera.com/news/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19 https://www.abcellera.com/news/abcellera-and-rallybio-announce-strategic-alliance-to-discover-develop-and-commercialize-novel-antibody-based-therapeutics-for-rare-diseases https://www.abcellera.com/news/abcellera-announces-25th-partnered-program-and-new-antibody-discovery-partnership https://www.abcellera.com/news/abcellera-announces-agreement-with-alloy-therapeutics-to-integrate-access-to-atx-gx-trade-humanized-mice-platform-for-antibody-discovery-programs https://www.abcellera.com/news/abcellera-announces-an-antibody-discovery-program-in-influenza-vaccine-research https://www.abcellera.com/news/abcellera-announces-changes-to-its-board-of-directors https://www.abcellera.com/news/abcellera-announces-closing-of-initial-public-offering-and-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares https://www.abcellera.com/news/abcellera-announces-collaboration-with-denali-therapeutics-to-discover-new-antibodies-to-treat-neurodegenerative-diseases https://www.abcellera.com/news/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology https://www.abcellera.com/news/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines https://www.abcellera.com/news/abcellera-announces-date-of-fourth-quarter-2020-financial-results-conference-call https://www.abcellera.com/news/abcellera-announces-expanded-research-collaboration-with-teva https://www.abcellera.com/news/abcellera-announces-first-patients-dosed-in-phase-2-portion-of-its-phase-1-2-clinical-trial-of-abcl635-for-the-treatment-of-vasomotor-symptoms-due-to-menopause https://www.abcellera.com/news/abcellera-announces-four-presentations-on-t-cell-engagers-at-aacr-2024 https://www.abcellera.com/news/abcellera-announces-multi-target-partnership-agreement-with-a-top-5-global-pharma https://www.abcellera.com/news/abcellera-announces-multi-target-research-collaboration-with-pfizer https://www.abcellera.com/news/abcellera-announces-multi-year-antibody-discovery-collaboration-with-lilly https://www.abcellera.com/news/abcellera-announces-partnership-with-niaid-vaccine-research-center-and-ichor-medical-systems-to-tackle-pandemic-viral-outbreaks https://www.abcellera.com/news/abcellera-announces-presentation-of-data-from-cd3-t-cell-engager-platform-at-sitc-2022 https://www.abcellera.com/news/abcellera-announces-presentation-of-in-vivo-data-on-psma-x-cd3-t-cell-engagers-at-aacr-2025 https://www.abcellera.com/news/abcellera-announces-presentation-on-t-cell-engager-platform-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2024 https://www.abcellera.com/news/abcellera-announces-pricing-of-initial-public-offering https://www.abcellera.com/news/abcellera-announces-resignation-of-board-member https://www.abcellera.com/news/abcellera-announces-secondary-private-sale-of-11-9-million-common-shares https://www.abcellera.com/news/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-has-denied-berkeley-lights-request-for-rehearing https://www.abcellera.com/news/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent https://www.abcellera.com/news/abcellera-announces-the-appointment-of-neil-aubuchon-as-chief-commercial-officer https://www.abcellera.com/news/abcellera-announces-therapeutic-antibody-discovery-collaboration-with-gilead-in-infectious-disease https://www.abcellera.com/news/abcellera-announces-two-presentations-on-t-cell-engager-discovery-at-aacr-2023 https://www.abcellera.com/news/abcellera-announces-two-t-cell-engager-presentations-at-sitc-2023 https://www.abcellera.com/news/abcellera-announces-virtual-presentations-at-investor-conferences-in-november https://www.abcellera.com/news/abcellera-appoints-andrew-booth-as-chief-financial-officer-and-tryn-stimart-as-general-counsel https://www.abcellera.com/news/abcellera-appoints-dr-sarah-noonberg-as-chief-medical-officer https://www.abcellera.com/news/abcellera-appoints-dr-stephen-quake-to-its-board-of-directors https://www.abcellera.com/news/abcellera-appoints-ester-falconer-ph-d-as-chief-technology-officer https://www.abcellera.com/news/abcellera-appoints-neil-berkley-as-chief-business-officer https://www.abcellera.com/news/abcellera-awarded-multi-year-contract-to-lead-the-development-of-a-rapid-response-platform-against-pandemic-viral-threats https://www.abcellera.com/news/abcellera-breaks-ground-on-global-headquarters-in-vancouver-and-expects-to-hire-hundreds-of-scientific-and-tech-professionals https://www.abcellera.com/news/abcellera-celebrates-the-opening-of-its-new-research-facility-and-corporate-headquarters https://www.abcellera.com/news/abcellera-closes-105-million-series-b-financing-to-further-advance-world-leading-antibody-drug-discovery-platform https://www.abcellera.com/news/abcellera-closes-series-a-led-by-dcvc-bio https://www.abcellera.com/news/abcellera-collaborates-with-autolus-on-antibody-discovery-project https://www.abcellera.com/news/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of--its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada https://www.abcellera.com/news/abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-receives-fda-emergency-use-authorization-for-covid-19 https://www.abcellera.com/news/abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-reduced-risk-of-covid-19-hospitalizations-and-death-by-70 https://www.abcellera.com/news/abcellera-discovered-antibody-bamlanivimab-to-be-developed-with-vir-7831-for-the-treatment-of-covid-19 https://www.abcellera.com/news/abcellera-discovered-antibody-granted-interim-authorization-by-health-canada-as-a-treatment-for-covid-19 https://www.abcellera.com/news/abcellera-discovered-antibody-prevented-covid-19-in-nursing-homes-and-reduced-risks-by-up-to-80-for-residents https://www.abcellera.com/news/abcellera-discovered-antibody-receives-u-s-fda-emergency-use-authorization-as-a-monotherapy-for-the-treatment-of-covid-19 https://www.abcellera.com/news/abcellera-discovered-bamlanivimab-together-with-etesevimab-authorized-as-the-first-and-only-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12 https://www.abcellera.com/news/abcellera-discovered-bamlanivimab-together-with-etesevimab-reduced-hospitalizations-and-prevented-death-in-phase-3-trial-for-early-covid-19 https://www.abcellera.com/news/abcellera-discovered-neutralizing-antibody-for-covid-19-enters-new-pragmatic-study-in-new-mexico https://www.abcellera.com/news/abcellera-doses-first-participants-in-a-phase-1-clinical-trial-of-abcl575 https://www.abcellera.com/news/abcellera-expands-collaboration-with-abbvie-to-develop-novel-t-cell-engagers-for-oncology https://www.abcellera.com/news/abcellera-expands-multi-target-antibody-discovery-collaboration-with-regeneron https://www.abcellera.com/news/abcellera-expands-technology-stack-with-acquisition-of-trianni-for-90-million https://www.abcellera.com/news/abcellera-files-patent-infringement-lawsuit-against-berkeley-lights-inc https://www.abcellera.com/news/abcellera-granted-us-patent-covering-its-trianni-mouse-reg-technology https://www.abcellera.com/news/abcellera-is-mobilizing-a-response-to-the-novel-coronavirus-outbreak-as-part-of-its-darpa-p3-program https://www.abcellera.com/news/abcellera-launches-antibody-discovery-collaboration-with-gsk https://www.abcellera.com/news/abcellera-named-one-of-canadas-top-growing-companies https://www.abcellera.com/news/abcellera-named-to-2016-life-science-emerging-rockets-list-of-high-growth-companies https://www.abcellera.com/news/abcellera-partners-with-angios-to-develop-therapeutics-to-combat-blindness-caused-by-diabetic-retinopathy https://www.abcellera.com/news/abcellera-partners-with-the-governments-of-canada-and-british-columbia-to-advance-drug-development-capabilities https://www.abcellera.com/news/abcellera-presents-data-on-applications-of-t-cell-engager-platform-at-sitc-2024 https://www.abcellera.com/news/abcellera-presents-data-on-t-cell-engager-platform-at-aacr-2022 https://www.abcellera.com/news/abcellera-presents-data-on-t-cell-engagers-against-four-tumor-targets-at-aacr-2024 https://www.abcellera.com/news/abcellera-presents-data-showing-preclinical-efficacy-of-psma-x-cd3-t-cell-engagers-at-aacr-2025 https://www.abcellera.com/news/abcellera-presents-new-data-on-further-development-and-characterization-of-t-cell-engager-platform-at-sitc-2022 https://www.abcellera.com/news/abcellera-presents-new-data-on-t-cell-engager-platform-at-aacr-2023 https://www.abcellera.com/news/abcellera-presents-new-data-on-two-t-cell-engager-programs-at-sitc-2023 https://www.abcellera.com/news/abcellera-presents-positive-preclinical-data-on-abcl575-at-the-sid-annual-meeting-2025 https://www.abcellera.com/news/abcellera-provides-covid-19-program-update-with-the-start-of-phase-3-clinical-trials-and-the-expansion-of-its-covid-19-antibody-database https://www.abcellera.com/news/abcellera-r-d-day-at-massbio-2023 https://www.abcellera.com/news/abcellera-receives-175-6-million-from-the-government-of-canada-to-discover-solutions-for-covid-19-and-build-a-manufacturing-facility-for-antibody-drugs https://www.abcellera.com/news/abcellera-receives-authorization-from-health-canada-to-initiate-a-phase-1-clinical-trial-of-abcl575 https://www.abcellera.com/news/abcellera-receives-authorization-from-health-canada-to-initiate-the-phase-1-clinical-trial-of-abcl635-for-vasomotor-symptoms-due-to-menopause https://www.abcellera.com/news/abcellera-receives-grant-to-help-fight-tuberculosis https://www.abcellera.com/news/abcellera-reports-full-year-2020-business-results https://www.abcellera.com/news/abcellera-reports-full-year-2022-business-results https://www.abcellera.com/news/abcellera-reports-full-year-2023-business-results https://www.abcellera.com/news/abcellera-reports-full-year-2024-business-results-e9309 https://www.abcellera.com/news/abcellera-reports-full-year-2025-business-results https://www.abcellera.com/news/abcellera-reports-q1-2021-business-results https://www.abcellera.com/news/abcellera-reports-q1-2023-business-results https://www.abcellera.com/news/abcellera-reports-q1-2024-business-results https://www.abcellera.com/news/abcellera-reports-q1-2025-business-results https://www.abcellera.com/news/abcellera-reports-q1-2026-business-results-announces-positive-interim-phase-1-clinical-data-for-abcl635 https://www.abcellera.com/news/abcellera-reports-q2-2021-business-results https://www.abcellera.com/news/abcellera-reports-q2-2023-business-results https://www.abcellera.com/news/abcellera-reports-q2-2024-business-results https://www.abcellera.com/news/abcellera-reports-q2-2025-business-results-first-participants-dosed-in-a-phase-1-clinical-trial-of-abcl635-for-vasomotor-symptoms https://www.abcellera.com/news/abcellera-reports-q3-2022-business-results https://www.abcellera.com/news/abcellera-reports-q3-2023-business-results https://www.abcellera.com/news/abcellera-reports-q3-2024-business-results https://www.abcellera.com/news/abcellera-reports-q3-2025-business-results https://www.abcellera.com/news/abcellera-signs-agreement-with-global-health-foundation-to-fight-infectious-disease https://www.abcellera.com/news/abcellera-to-collaborate-with-biogen-to-discover-therapeutic-antibodies-for-neurological-conditions https://www.abcellera.com/news/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call https://www.abcellera.com/news/abcellera-to-participate-at-upcoming-investor-conferences-in-march https://www.abcellera.com/news/abcellera-to-participate-at-upcoming-investor-conferences-in-may-and-june-3c4a0 https://www.abcellera.com/news/abcellera-to-participate-at-upcoming-investor-conferences-in-november-and-december-2025 https://www.abcellera.com/news/abcellera-to-participate-at-upcoming-investor-conferences-in-september https://www.abcellera.com/news/abcellera-to-participate-virtually-in-the-truist-securities-ai-symposium---biotech-tools https://www.abcellera.com/news/abcellera-to-present-at-the-2022-bloom-burton-co-healthcare-investor-conference-on-may-2-2022 https://www.abcellera.com/news/abcellera-to-present-at-the-2023-bloom-burton-co-healthcare-investor-conference-on-april-25-2023 https://www.abcellera.com/news/abcellera-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-on-january-11-2023 https://www.abcellera.com/news/abcellera-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-january-10-2024 https://www.abcellera.com/news/abcellera-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-14-2026 https://www.abcellera.com/news/abcellera-to-present-at-the-bloom-burton-healthcare-conference-on-april-16-2024 https://www.abcellera.com/news/abcellera-to-present-at-the-cowen-43rd-annual-health-care-conference-on-march-6-2023 https://www.abcellera.com/news/abcellera-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-on-june-13-2023 https://www.abcellera.com/news/abcellera-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference-on-june-10-2024 https://www.abcellera.com/news/abcellera-to-present-at-the-jefferies-london-healthcare-conference-on-november-14-2023 https://www.abcellera.com/news/abcellera-to-present-at-the-piper-sandler-35th-annual-healthcare-conference https://www.abcellera.com/news/abcellera-to-present-at-the-svb-leerink-global-healthcare-conference https://www.abcellera.com/news/abcellera-to-present-at-the-svb-securities-global-biopharma-conference-on-february-15-2023 https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-december-and-january https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-march https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-march-and-april-2026 https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-may-and-june-2026 https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-november https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-november-ae1ae https://www.abcellera.com/news/abcellera-to-present-at-upcoming-investor-conferences-in-september https://www.abcellera.com/news/abcellera-to-present-virtually-at-berenberg-conference-on-may-18-2021 https://www.abcellera.com/news/abcellera-to-present-virtually-at-the-11th-annual-svb-leerink-global-healthcare-conference-on-february-17-2022 https://www.abcellera.com/news/abcellera-to-present-virtually-at-the-bofa-securities-tech-solutions-for-drug-discovery-conference https://www.abcellera.com/news/abcellera-to-present-virtually-at-upcoming-investor-conferences https://www.abcellera.com/news/abcellera-to-report-first-quarter-2021-financial-results-on-may-13-2021 https://www.abcellera.com/news/abcellera-to-report-first-quarter-2022-financial-results-on-may-10-2022 https://www.abcellera.com/news/abcellera-to-report-first-quarter-2023-financial-results-on-may-4-2023 https://www.abcellera.com/news/abcellera-to-report-first-quarter-2024-financial-results-on-may-7-2024 https://www.abcellera.com/news/abcellera-to-report-first-quarter-2025-financial-results-on-may-8-2025 https://www.abcellera.com/news/abcellera-to-report-first-quarter-2026-financial-results-on-may-11-2026 https://www.abcellera.com/news/abcellera-to-report-full-year-2021-financial-results-on-february-24-2022 https://www.abcellera.com/news/abcellera-to-report-full-year-2022-business-results-on-february-21-2023 https://www.abcellera.com/news/abcellera-to-report-full-year-2023-financial-results-on-february-20-2024 https://www.abcellera.com/news/abcellera-to-report-full-year-2024-financial-results-on-february-27-2025 https://www.abcellera.com/news/abcellera-to-report-full-year-2025-financial-results-on-february-24-2026 https://www.abcellera.com/news/abcellera-to-report-second-quarter-2021-financial-results-on-august-12-2021 https://www.abcellera.com/news/abcellera-to-report-second-quarter-2022-financial-results-on-august-9-2022 https://www.abcellera.com/news/abcellera-to-report-second-quarter-2023-financial-results-on-august-3-2023 https://www.abcellera.com/news/abcellera-to-report-second-quarter-2024-financial-results-on-august-6-2024 https://www.abcellera.com/news/abcellera-to-report-second-quarter-2025-financial-results-on-august-7-2025 https://www.abcellera.com/news/abcellera-to-report-third-quarter-2021-financial-results-on-november-9-2021 https://www.abcellera.com/news/abcellera-to-report-third-quarter-2022-financial-results-on-november-8-2022 https://www.abcellera.com/news/abcellera-to-report-third-quarter-2023-financial-results-on-november-2-2023 https://www.abcellera.com/news/abcellera-to-report-third-quarter-2024-financial-results-on-november-4-2024 https://www.abcellera.com/news/abcellera-to-report-third-quarter-2025-financial-results-on-november-6-2025 https://www.abcellera.com/news/abcellera-viking-global-investors-and-arrowmark-partners-collaborate-to-launch-new-biotech-companies https://www.abcellera.com/news/abcellera-wins-fast-companys-innovative-team-of-the-year-award-and-is-named-to-the-2020-best-workplaces-for-innovators-list https://www.abcellera.com/news/abcelleras-first-program-with-regeneron-in-multi-target-collaboration-advances-in-preclinical-development https://www.abcellera.com/news/abcelleras-microfluidic-cell-culture-patent-affirmed-valid-by-the-u-s-court-of-appeals-for-the-federal-circuit https://www.abcellera.com/news/abcelleras-rapid-pandemic-response-platform-contributes-to-the-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment https://www.abcellera.com/news/abcelleras-statement-on-the-neutralization-activity-of-its-monoclonal-antibody-therapies-against-the-omicron-variant-of-concern https://www.abcellera.com/news/acop-2025 https://www.abcellera.com/news/admare-launches-abdera-with-abcellera-as-a-founding-partner https://www.abcellera.com/news/aet-usa-2024 https://www.abcellera.com/news/antibody-discovery-selection-and-screening-digital-week https://www.abcellera.com/news/antibody-engineering-and-therapeutics-eu-2025 https://www.abcellera.com/news/antibody-engineering-and-therapeutics-eu-virtual-2020 https://www.abcellera.com/news/antibody-engineering-and-therapeutics-us-2020 https://www.abcellera.com/news/antibody-engineering-therapeutics-asia-virtual-scientific-forum https://www.abcellera.com/news/antibody-engineering-therapeutics-eu-2021 https://www.abcellera.com/news/antibody-engineering-therapeutics-eu-2023 https://www.abcellera.com/news/antibody-engineering-therapeutics-eu-2024 https://www.abcellera.com/news/antibody-engineering-therapeutics-us-2021 https://www.abcellera.com/news/antibody-engineering-therapeutics-usa-2022 https://www.abcellera.com/news/antibody-engineering-therapeutics-usa-2023 https://www.abcellera.com/news/bc-cancer-research-day-2020 https://www.abcellera.com/news/bio-2022 https://www.abcellera.com/news/bio-digital-2020 https://www.abcellera.com/news/bio-europe-2022 https://www.abcellera.com/news/bio-europe-spring-digital-2021 https://www.abcellera.com/news/bio-immunology-virtual-partnering-event https://www.abcellera.com/news/bio-oncology-virtual-partnering-event https://www.abcellera.com/news/biocoms-global-life-science-partnering-conference https://www.abcellera.com/news/biocoms-global-life-science-partnering-conference-97a55 https://www.abcellera.com/news/biologics-europe-online https://www.abcellera.com/news/bioprocess-international-2022 https://www.abcellera.com/news/cell-culture-engineering-xviii https://www.abcellera.com/news/cqdm-and-brain-canada-inject-1-m-in-top-bc-biotech-firm-abcellera-to-advance-discovery-platform-for-next-generation-antibody-therapeutics https://www.abcellera.com/news/discovery-on-target-2020 https://www.abcellera.com/news/discovery-on-target-2021 https://www.abcellera.com/news/discovery-on-target-2024 https://www.abcellera.com/news/discovery-on-target-2025 https://www.abcellera.com/news/discovery-to-commercialization-2020 https://www.abcellera.com/news/dr-michael-hayden-joins-abcellera-board-of-directors https://www.abcellera.com/news/drug-discovery-world-cancer-research-summit-2023 https://www.abcellera.com/news/ema-advises-use-of-abcellera-discovered-bamlanivimab-alone-or-together-with-etesevimab-to-treat-confirmed-covid-19-patients https://www.abcellera.com/news/emergency-use-authorization-of-abcellera-discovered-bamlanivimab-administered-with-etesevimab-expanded-by-the-fda-to-include-post-exposure-prophylaxis-for-the-prevention-of-covid-19 https://www.abcellera.com/news/eqrx-and-abcellera-announce-collaboration-to-accelerate-the-advancement-of-new-innovative-medicines https://www.abcellera.com/news/european-antibody-therapeutics-xchange-2021 https://www.abcellera.com/news/festival-of-biologics-2024 https://www.abcellera.com/news/festival-of-biologics-eu-2023 https://www.abcellera.com/news/festival-of-biologics-eu-2024 https://www.abcellera.com/news/festival-of-biologics-europe-2021 https://www.abcellera.com/news/festival-of-biologics-europe-2022 https://www.abcellera.com/news/festival-of-biologics-usa-2020 https://www.abcellera.com/news/festival-of-biologics-usa-2021 https://www.abcellera.com/news/festival-of-biologics-usa-2022 https://www.abcellera.com/news/festival-of-biologics-usa-2023 https://www.abcellera.com/news/festival-of-biologics-usa-2024 https://www.abcellera.com/news/festival-of-biologics-usa-2025 https://www.abcellera.com/news/fierce-biotech-names-abcellera-a-fierce-15-company-of-2020 https://www.abcellera.com/news/fierce-business-development-licensing-summit-2023 https://www.abcellera.com/news/fight-against-duchenne-muscular-dystrophy-gets-major-funding-boost https://www.abcellera.com/news/gordon-research-conference-antibody-biology-and-engineering-2022 https://www.abcellera.com/news/immuno-oncology-summit-eu-2023 https://www.abcellera.com/news/immuno-oncology-summit-usa-2024 https://www.abcellera.com/news/interim-data-reported-for-abcellera-discovered-covid-19-antibody-in-phase-2-clinical-trials https://www.abcellera.com/news/invetx-announces-15-million-series-a-financing-and-industry-leading-partnerships-for-animal-biopharmaceutical-development https://www.abcellera.com/news/ispe-biotechnology-conference-2023 https://www.abcellera.com/news/john-montalbano-joins-abcelleras-board-of-directors https://www.abcellera.com/news/jpm-annual-healthcare-meeting-2023 https://www.abcellera.com/news/jpm-annual-healthcare-meeting-2024 https://www.abcellera.com/news/keystone-symposia-on-molecular-cellular-biology-2021 https://www.abcellera.com/news/keystone-symposium-multispecific-immune-cell-engagers-for-cancer-immunotherapy https://www.abcellera.com/news/life-sciences-bc-access-to-innovation-2021 https://www.abcellera.com/news/life-sciences-bc-access-to-innovation-2022 https://www.abcellera.com/news/lifesciences-bc-blakes-breakfast-2020 https://www.abcellera.com/news/lifesciences-bc-growth-stage-company-of-the-year-awarded-to-abcellera https://www.abcellera.com/news/lilly-to-supply-614-000-additional-doses-of-abcellera-discovered-bamlanivimab-together-with-etesevimab-to-the-u-s-government-for-the-treatment-or-post-exposure-prevention-of-covid-19 https://www.abcellera.com/news/lilly-to-supply-an-additional-150-000-doses-of-abcellera-discovered-antibody-bebtelovimab-to-the-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options https://www.abcellera.com/news/lilly-to-supply-the-eu-and-eea-with-up-to-220-000-doses-of-bamlanivimab-together-with-etesevimab-for-the-treatment-of-confirmed-covid-19 https://www.abcellera.com/news/lilly-to-supply-up-to-600-000-doses-of-abcellera-discovered-antibody-bebtelovimab-to-the-u-s-government-in-ongoing-effort-to-provide-covid-19-treatments https://www.abcellera.com/news/longwood-healthcare-leaders-spring-mit-conference-2023 https://www.abcellera.com/news/lorne-proteins-2023 https://www.abcellera.com/news/mars-impact-health-2021 https://www.abcellera.com/news/mars-impact-health-2022 https://www.abcellera.com/news/molecular-med-tri-con-virtual https://www.abcellera.com/news/new-abcellera-discovered-antibody-that-neutralizes-viral-variants-of-covid-19-ly-cov1404-enters-clinical-trials https://www.abcellera.com/news/news-abcellera-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-for-2020 https://www.abcellera.com/news/pda-fda-joint-regulatory-conference https://www.abcellera.com/news/pegs-boston-2022 https://www.abcellera.com/news/pegs-boston-2023 https://www.abcellera.com/news/pegs-boston-2024 https://www.abcellera.com/news/pegs-boston-2025 https://www.abcellera.com/news/pegs-boston-virtual-2021 https://www.abcellera.com/news/pegs-eu-2022 https://www.abcellera.com/news/pegs-eu-2023 https://www.abcellera.com/news/pegs-eu-2024 https://www.abcellera.com/news/pegs-eu-2025 https://www.abcellera.com/news/pegs-europe-2021 https://www.abcellera.com/news/pegs-europe-2023 https://www.abcellera.com/news/pegs-europe-virtual-2020 https://www.abcellera.com/news/pegs-virtual-interactive-global-summit-2020 https://www.abcellera.com/news/peptalk-2020 https://www.abcellera.com/news/peptalk-2022 https://www.abcellera.com/news/peptalk-virtual-2021 https://www.abcellera.com/news/peter-thiel-joins-abcelleras-board-of-directors https://www.abcellera.com/news/prelude-therapeutics-and-abcellera-enter-partnership-to-develop-first-in-class-precision-antibody-drug-conjugates-in-oncology https://www.abcellera.com/news/providence-health-care-innovation-seminar-2021 https://www.abcellera.com/news/published-peer-reviewed-data-demonstrate-bamlanivimabs-high-potency-against-sars-cov-2-and-support-its-use-as-a-foundational-antibody-therapy-to-treat-and-prevent-covid-19 https://www.abcellera.com/news/sfu-ubc-pda-career-networking-night https://www.abcellera.com/news/sitc-2024 https://www.abcellera.com/news/sitc-annual-meeting-2022 https://www.abcellera.com/news/sitc-annual-meeting-2023 https://www.abcellera.com/news/society-for-investigative-dermatology-annual-meeting-2025 https://www.abcellera.com/news/synbiobeta-2019 https://www.abcellera.com/news/synbiobeta-biopharma-day-2021 https://www.abcellera.com/news/tachyon-and-abcellera-collaborate-to-develop-novel-antibody-therapeutic-targeting-tgf-beta-superfamily-member-for-the-treatment-of-cancer https://www.abcellera.com/news/teva-and-abcellera-enter-into-agreement-to-discover-rare-monoclonal-antibodies https://www.abcellera.com/news/the-11th-annual-don-rix-distinguished-keynote-address https://www.abcellera.com/news/the-data-effect-how-to-build-a-digital-society-2022 https://www.abcellera.com/news/us-east-coast-antibody-therapeutics-e-xchange-2020 https://www.abcellera.com/news/us-east-coast-antibody-therapeutics-xchange https://www.abcellera.com/news/versant-ventures-collaborates-with-abcellera-to-accelerate-drug-development-for-its-portfolio-of-biotech-companies https://www.abcellera.com/news/west-coast-antibody-therapeutics-xchange https://www.abcellera.com/news/world-bispecific-summit-2023 https://www.abcellera.com/publications/a-rational-approach-for-selecting-cd3-binding-antibodies-for-t-cell-engager-development-581a2 https://www.abcellera.com/publications/breaking-barriers-to-access-intracellular-targets-with-t-cell-engagers-discovery-of-diverse-developable-and-ultra-specific-antibodies-against-a-mage-a4-pmhc https://www.abcellera.com/publications/development-of-psma-x-cd3-t-cell-engagers-using-an-integrated-functional-approach-7a608 https://www.abcellera.com/publications/discovery-of-diverse-gpcr-targeted-antibodies-using-integrated-technologies-1fd33 https://www.abcellera.com/publications/diverse-cd28-binding-antibodies-for-costimulatory-t-cell-engager-development-33288 https://www.abcellera.com/publications/functional-and-specific-t-cell-engagers-for-a-peptide-mhc-tumor-target https://www.abcellera.com/publications/identifying-t-cell-engagers-with-optimal-potency-and-cytokine-release-profiles-with-a-diverse-panel-of-cd3-binding-antibodies-924bf https://www.abcellera.com/publications/preclinical-development-of-abcl575-a-half-life-extended-anti-ox40l-monoclonal-antibody-for-the-treatment-of-autoimmune-conditions https://www.abcellera.com/publications/profiling-bispecific-t-cell-engagers-strategies-for-enhancing-potency-while-minimizing-cytokine-release-2b5b2 https://www.abcellera.com/publications/redirecting-t-cells-to-tumor-targets-with-functionally-diverse-cd3-binding-antibodies https://www.abcellera.com/publications/streamlining-t-cell-engager-development-with-a-diverse-panel-of-fully-human-cd3-binding-antibodies-bispecific-engineering-technology-and-an-integrated-discovery-engine https://www.abcellera.com/publications/target-dependent-considerations-for-the-design-of-bispecific-t-cell-engagers-e8a58 https://www.abcellera.com/publications/targeting-intracellular-tumor-antigens-to-fight-cancer-discovery-and-development-of-functional-and-specific-t-cell-engagers-against-a-mage-a4-pmhc-c2255 https://www.abcellera.com/posters/conference-psma-poster https://www.abcellera.com/downloads/quality-policy